The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.
本发明涉及使用酰基
硫脲或酰基
脲衍
生物治疗涉及组织功能障碍的病理情况,该功能障碍与Hedgehog蛋白信号通路的失调有关,并且涉及作为药物产品的新型酰基
硫脲或酰基
脲衍
生物,它们的用途以及含有它们的药物组成物。